SBFM FY 2024 Earnings — Sunshine Biopharma, Inc. Revenue & Financial Results | Market Cap Arena

SBFMSunshine Biopharma, Inc.

$6M

FY 2024 Earnings

Healthcare Drug Manufacturers - Specialty & Generic

Income Statement

Revenue

$35M+44.7% YoY

Gross Profit

$11M30.6% margin

Operating Income

-$6M-16.7% margin

Net Income

-$5M-14.7% margin

EPS (Diluted)

$-7.32

Cash Flow

Operating Cash Flow

-$13M

Free Cash Flow

-$15M

Stock-Based Comp.

$0

Balance Sheet

Total Assets

$31M

Total Liabilities

$7M

Stockholders' Equity

$24M

Cash & Equivalents

$10M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$35M	$24M	+44.7%
Gross Profit	$11M	$8M	+28.0%
Operating Income	-$6M	-$5M	-21.5%
Net Income	-$5M	-$5M	-13.9%